Nyheter

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

Autoimmune Type 1 Diabetes (T1D) can be detected through islet autoantibody testing years before symptoms appear.^1-2 The video here explains how the condition progresses silently through presymptomatic stages, with beta cell destruction occurring long before symptom onset and clinical diagnosis.^4-8

Parent's experiences of stage 3 diagnosis of T1D.

Understanding the full scope of AD—the unseen burden on patients.

Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).¹

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.^1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.^3,4